Head-to-Head chemo trial aims to better control tough lymphoma
NCT ID NCT07450508
Summary
This study directly compared two different chemotherapy combinations for adults whose classical Hodgkin lymphoma had returned or did not respond to initial treatment. The goal was to see which regimen—BEGEV or GDP—was more effective at shrinking the cancer and getting patients ready for a stem cell transplant. Patients received their assigned chemo every 3 weeks and were followed for one year to track their response and survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA RELAPSED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Institute
Cairo, From Elkhart, 11796, Egypt
Conditions
Explore the condition pages connected to this study.